Examples of using Non-proprietary name in English and their translations into Polish
{-}
-
Medicine
-
Official
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
International non-proprietary name INN.
OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Crestor 5 mg International Non-Proprietary Name INN.
International Non-proprietary Name(INN): interferon alfa-2a.
OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Lansopon 15 mg and 30 mg International Non-Proprietary Name INN.
International non-proprietary name(INN): mecasermin rinfabate.
OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Lansoprazol HEXAL 15 mg and 30 mg International Non-Proprietary Name INN.
International Non-Proprietary Name(INN): salmeterol/ fluticasone.
OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Lansoprazol AbZ-Pharma 15 mg and 30 mg International Non-Proprietary Name INN.
International Non-Proprietary Name(INN): doxycycline monohydrate.
OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Lansoprazol-ratiopharm 15 mg and 30 mg International Non-Proprietary Name INN.
International non-proprietary name(INN): fenofibrate/ metformin hydrochloride.
OPINION FOLLOWING AN ARTICLE 351 REFERRAL FOR Suramox 15% LA and its associated name Stabox 15% LA International Non-Proprietary Name INN.
Common name: The international non-proprietary name recommended by the World Health Organization, or, if one does not exist, the usual common name. .
For the purposes of this provision, all the linguistic versions of the INN(international non-proprietary name) shall be considered to be the same name. .
The introduction should include proprietary name, non-proprietary name or common name of the drug substance, company name, dosage form(s), tugevus(s), route of administration, and proposed indication s.
QUESTIONS AND ANSWERS ON THE RECOMMENDATION FOR REFUSAL OF A MARKETING AUTHORISATION APPLICATION for VERAFLOX International Non-proprietary Name(INN): pradofloxacin.
Both the invented name Kadcyla and its full non-proprietary name(trastuzumab emtansine) should be used and confirmed when prescribing, preparing the infusion solution and administering Kadcyla to patients.
Therefore, two pharmacologically related protein substances of the same group(for example,two biological compounds having the same International Non-proprietary name(INN) sub-stem) would normally be considered similar.
Qualitative and quantitative particulars of all the constituents of the veterinary medicinal product, using the usual terminology, but not empirical chemical formulae andgiving the international non-proprietary name recommended by the World Health Organization, where such a name exists;
COUNCIL REGULATION(EC) No 467/97 of 3 March 1997 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an'international non-proprietary name'(INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals and withdrawing duty-free treatment as pharmaceutical products from certain INNs whose predominant use is not pharmaceutical.
The Council adopted a regulation concerning the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an"international non-proprietary name"(INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals 59/10.
Duty-free treatment for specified pharmaceutical active ingredients bearing an'international non-proprietary name'(INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals.
A statement of the active substances expressed qualitatively and quantitatively per dosage unit or according to the form of administration for a particular volume or weight,using the international non-proprietary names recommended by the World Health Organization, where such names exist or, where no such names exist, the usual non-proprietary names; .
The identity of each ingredient, in particular its chemical name, the CTFA name, the European Pharmacopoeia name, the international non-proprietary names recommended by the World Health Organization, the Einecs, Iupac, CAS and colour index numbers, and the common name referred to in Article 7 2.
Whereas the participants in those discussions concluded that in addition to products falling within the Harmonized System(HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941,duty-free treatment should be given to designated pharmaceutical active ingredients bearing an'international non-proprietary name'(INN) from the World Health Organization as well as specified salts, esters and hydrates of such INNs, and also to designated products used for the production and manufacture of finished products;
The CAS, Einecs and colour index numbers, the chemical name, the Iupac name, the INCI(1) name, the European Pharmacopoeia name, the international non-proprietary name recommended by the World Health Organization, and the common nomenclature name referred to in Article 7(2) of Directive 76/768/EEC, where they exist.